文献速递临床试验与 GCP真实世界研究与卫生经济

SANAD II研究:丙戊酸与左乙拉西坦治疗新诊断全面性或不可分类癫痫的有效性与成本效果

The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
PubMed 文献 · Lancet · 2021-01-01

SANAD II是一项开放标签、非劣效性、多中心4期随机对照试验,纳入520例新诊断全面性或不可分类癫痫患者,比较左乙拉西坦与丙戊酸作为一线治疗。

要点

  • 符合方案分析显示丙戊酸在12个月缓解方面优于左乙拉西坦。
  • 成本效用分析中左乙拉西坦被丙戊酸占优,增量净健康效益为负。

核心结论

  • 与丙戊酸相比,左乙拉西坦在临床有效性和成本效果方面均不占优势。

研究设计与样本

  • 开放标签、非劣效性、多中心4期随机对照试验,在英国69个中心招募520例5岁及以上新诊断全面性或不可分类癫痫患者。

主要发现

  • 符合方案分析显示丙戊酸的12个月缓解优于左乙拉西坦。
  • 丙戊酸组96例(37%)和左乙拉西坦组107例(42%)报告不良反应。

临床怎么用

  • 对于新诊断全面性或不可分类癫痫患者,丙戊酸仍是更有效且更具成本效果的一线选择。
  • 对于育龄期女性,需结合丙戊酸的致畸性风险与左乙拉西坦疗效较低的证据进行个体化讨论。

局限性

  • 开放标签设计,参与者和研究者知晓治疗分配。
  • 结果主要适用于5岁及以上新诊断全面性或不可分类癫痫患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Valproate is a first-line treatment for patients with newly diagnosed idiopathic generalised or difficult to classify epilepsy, but not for women of child-bearing potential because of teratogenicity. Levetiracetam is increasingly prescribed for these patient populations despite scarcity of evidence of clinical effectiveness or cost-effectiveness. We aimed to compare the long-term clinical effectiveness and cost-effectiveness of levetiracetam compared with valproate in participants with newly diagnosed generalised or unclassifiable epilepsy. METHODS: We did an open-label, randomised controlled trial to compare levetiracetam with valproate as first-line treatment for patients with generalised or unclassified epilepsy. Adult and paediatric neurology services (69 centres overall) across the UK recruited participants aged 5 years or older (with no upper age limit) with two or more unprovoked generalised or unclassifiable seizures. Participants were randomly allocated (1:1) to receive either levetiracetam or valproate, using a minimisation programme with a random element utilising factors. Participants and investigators were aware of treatment allocation. For participants aged 12 years or older, the initial advised maintenance doses were 500 mg twice per day for levetiracetam and valproate, and for children aged 5-12 years, the initial daily maintenance doses advised were 25 mg/kg for valproate and 40 mg/kg for levetiracetam. All drugs were administered orally. SANAD II was designed to assess the non-inferiority of levetiracetam compared with valproate for the primary outcome time to 12-month remission. The non-inferiority limit was a hazard ratio (HR) of 1·314, which equates to an absolute difference of 10%. A HR greater than 1 indicated that an event was more likely on valproate. All participants were included in the intention-to-treat (ITT) analysis. Per-protocol (PP) analyses excluded participants with major protocol deviations and those who were subsequently diagnosed as not having epilepsy. Safety analyses included all participants who received one dose of any study drug. This trial is registered with the ISRCTN registry, 30294119 (EudraCt number: 2012-001884-64). FINDINGS: 520 participants were recruited between April 30, 2013, and Aug 2, 2016, and followed up for a further 2 years. 260 participants were randomly allocated to receive levetiracetam and 260 participants to receive valproate. The ITT analysis included all participants and the PP analysis included 255 participants randomly allocated to valproate and 254 randomly allocated to levetiracetam. Median age of participants was 13·9 years (range 5·0-94·4), 65% were male and 35% were female, 397 participants had generalised epilepsy, and 123 unclassified epilepsy. Levetiracetam did not meet the criteria for non-inferiority in the ITT analysis of time to 12-month remission (HR 1·19 [95% CI 0·96-1·47]); non-inferiority margin 1·314. The PP analysis showed that the 12-month remission was superior with valproate than with levetiracetam. There were two deaths, one in each group, that were unrelated to trial treatments. Adverse reactions were reported by 96 (37%) participants randomly assigned to valproate and 107 (42%) participants randomly assigned to levetiracetam. Levetiracetam was dominated by valproate in the cost-utility analysis, with a negative incremental net health benefit of -0·040 (95% central range -0·175 to 0·037) and a probability of 0·17 of being cost-effectiveness at a threshold of £20 000 per quality-adjusted life-year. Cost-effectiveness was based on differences between treatment groups in costs and quality-adjusted life-years. INTERPRETATION: Compared with valproate, levetiracetam was found to be neither clinically effective nor cost-effective. For girls and women of child-bearing potential, these results inform discussions about benefit and harm of avoiding valproate. FUNDING: National Institute for Health Research Health Technology Assessment Programme.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Marson A, Burnside G, Appleton R, et al. The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. Lancet. 2021. PMID: 33838758. doi:10.1016/S0140-6736(21)00246-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。